A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Phoenix Ho, MD
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- City of Hope National Medical Center
Duarte, California, United States
- University of Colorado Hospital / University of Colorado
Aurora, Colorado, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Hudson Valley Hematology and Oncology Associates/new York Medical College
Hawthorne, New York, United States
- Md Anderson Cancer Center / University of Texas
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2016
- Primary completion
- 6 Apr 2018
- Completion
- 6 Apr 2018
- Last update posted
- 14 May 2018
- Registered enrollment
- 17
- Registry id
- NCT02848248
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.